Galápagos

SAPHIRA 1 topline results

Onno van de Stolpe, CEO
Dr Piet Wigerinck, CSO

Webcast
21 December 2016

Disclaimer

This presentation has been prepared by Galapagos and is furnished to you by Galapagos solely for your information.

This presentation contains forward-looking statements, including (without limitation) statements concerning the progress of our clinical pipeline, the slides captioned "2016: great execution year" "CF Portfolio" "SAPHIRA 1 topline", statements regarding the development of the triple combination therapy CF program, statements regarding the expected timing, design and readouts of ongoing and planned clinical trials (i) with filgotinib in RA and IBD, (ii) in the CF program, (iii) with GLPG1690 in IPF, (iv) with GLPG1972 in OA, (v) with MOR106 in inflammation, and expectations regarding the commercial potential of our product candidates. When used in this presentation, the words "anticipate," "believe," "can," "could," "estimate," "expect," "intend," "is designed to," "may," "might," "will," "plan," "potential," "possible," "predict," "objective," "should," and similar expressions are intended to identify forward-looking statements.

Forward-looking statements involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition, performance or achievements of Galapagos, or industry results, to be materially different from any future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. Among the factors that may result in differences are the inherent uncertainties associated with competitive developments, clinical trial and product development activities, regulatory approval requirements (including that data from the company's development programs may not support registration or further development of its compounds due to safety, efficacy or other reasons), reliance on third parties (including Galapagos' collaboration partner for cystic fibrosis, AbbVie, and its collaboration partner for filgotinib, Gilead) and estimating the commercial potential of its product candidates. A further list and description of these risks, uncertainties and other risks can be found in Galapagos' Securities and Exchange Commission filing and reports, including Galapagos' most recent 20-F filing and subsequent reports filed by Galapagos with the SEC. Given these uncertainties, you are advised not to place any undue reliance on such forward-looking statements.

All statements contained herein speak only as of the release date of this document. Galapagos expressly disclaims any obligation to update any statement in this document to reflect any change or future development with respect thereto, any future results, or any change in events, conditions and/or circumstances on which any such statement is based, unless specifically required by law or regulation.

Neither Galapagos nor any of its officers, employees, advisers, or agents makes any representation or warranty, express or implied, as to any matter or as to the truth, accuracy, or completeness of any statement made in this presentation, made in conjunction therewith or in any accompanying materials or made at any time, orally or otherwise, in connection with the matters referred to herein and all liability in respect of any such matter or statements is expressly excluded.

2016: great execution year

- Closure of the deal with Gilead on filgotinib, $725 M received in January
- Filgotinib: Ph 3 studies started in RA & CD, Ph 2/3 in UC
- Endoscopic data of filgotinib treatment in CD presented
- CF: all components of triple therapy in human trials
- CF collaboration with AbbVie expanded
- '1690 started Ph2a in IPF
- MOR106 antibody started in atopic dermatitis
- Galapagos included in BEL20, AEX and Stoxx Europe indices

CF portfolio

Preclinical	Ph1	Ph2	Status	
potentiator '1837			Ph2 results:	disclosed
potentiator '2451			Ph1 results:	H1 '17
potentiator '3067			Ph1 start:	H1 '17
C1 corrector '2222			Ph2 start:	✓
C1 corrector '2851			Ph1 start:	H2 '17
C2 corrector '2737			Ph1 results:	H1 '17
C2 corrector '3221			Ph1 start:	H2 '17

On track to have triple in patients by mid-2017

SAPHIRA 1

‘1837 Ph2a open label trial



26 patients harboring a G551D mutation

- 25 Kalydeco treated & 1 naive patient
- recruited at 16 centers in 6 EU countries & Australia
- study executed within 1 year
- primary endpoints: safety & tolerability
- secondary endpoints: sweat chloride, FEV1, plasma levels

Patient disposition



Baseline characteristics

Age, years, mean Range	30 19 - 51
Weight, kg, mean	68
Male, n (%)	12 (46%)
F508del on 2nd allele	18/26 (69%)
[Sw Cl]@Baseline, mmol/L, mean (range)	98 (63 – 116)
Percent predicted FEV1, mean (range) < 40%, n (%) 40% – 60%, n (%) 60% – 80%, n (%) > 80%, n (%)	69 (30 – 104) 2 (8%) 7 (28%) 8 (32%) 8 (32%)
Kalydeco use, n (%) Mean duration, days (range)	25 (96%) 1189 (310 – 2359)

Dose selection

In vitro efficacy curve relative to predicted levels in G551D



Galápagos

Sweat chloride vs exposure



Galápagos

Sweat chloride vs exposure



Galápagos

Sweat chloride

'1837 exposure on Day 29



Galápagos

Effect on FEV1



Galápagos

Safety & tolerability

Adverse events

- Generally well-tolerated
- Three serious adverse events in 2 patients
  - 1 patient with non-cardiac CPK increase
  - 1 patient with distal intestinal obstruction syndrome during screening period & pulmonary exacerbation (D28) of CF, resulting in hospitalization
- All other adverse events mild/moderate
- Most common adverse events: headaches, fatigue
- Some respiratory adverse events in 1st week
  - low incidence in weeks 2-4

SAPHIRA 1 topline

Conclusions on '1837

- First potentiator after Kalydeco to show positive results in G551D
- Appears safe & well tolerated
- Statistically significant decreases in sweat chloride
- Full restoration of FEV1 % loss from Kalydeco washout
- Supports our predictive *in vitro* assays
- Strengthening of our dosing modelling for triple combination